Search
Home / Registries and Studies / Lactation Study

Lactation Study

A study to assess the amount of palopegteriparatide in breast milk of lactating females requiring palopegteriparatide

Inclusion Criteria

Women, age 18 or older, enrolled in the Palopegteriparatide Pregnancy Registry
Lactating females who are receiving therapeutic doses of palopegteriparatide as part of usual care, have chosen to breastfeed their infant(s), and have been taking palopegteriparatide for at least 14 days prior to sample collection

Exclusion Criteria

Presence of any medical condition that, in the opinion of the investigator, may impair the ability to breastfeed during this study, including but not limited to mastitis and nipple malformation

For additional study information and for inclusion/exclusion criteria: Healthcare providers may visit ClinicalTrials.gov (NCT07264634).

Ascendis Pharma does not recommend or endorse using its medications in a way that conflicts with FDA-approved labeling.

Welcome to the Ascendis Pharma US Medical Website

This website is a self-service hub of scientific information, educational resources, and published clinical data related to Ascendis Pharma’s treatments and therapeutic areas of interest. This website is intended for healthcare professionals in the United States and its territories. By accessing and searching across this website, you confirm the unsolicited nature of your inquiry and interest. The website is made available by Ascendis Pharma’s US Medical Affairs organization and is provided as a resource for informational, non-promotional, and scientific exchange purposes only.

This website may contain information about products or uses that have not been approved by the U.S. Food and Drug Administration (FDA) and does not establish the safety or efficacy of these products or uses. There is no guarantee that investigational products and uses will receive FDA approval. The content of this site is not medical advice. Ascendis Pharma is unable to provide treatment recommendations outside of the approved product label. Treatment decisions should always be based on institutional standards and the treating healthcare professional’s clinical judgement based on the individual patient’s needs. Please review the full prescribing information for safety information and directions for use before prescribing medications. By selecting the option below, you acknowledge that you are a US healthcare professional.

Please report any adverse events related to any of our products by calling us at 1-844-442-7236.

You are encouraged to report side effects of prescription drugs to the FDA.
Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.

I am a US HCP I am a US Patient or Caregiver I am not based in the US

You are now leaving the

Ascendis Pharma US Medical Website

You are now leaving the Ascendis Pharma US Medical Website. Third-party websites are not owned, endorsed, or controlled by Ascendis Pharma. Ascendis Pharma is not responsible for the content on third-party websites. Any opinions, claims, or comments expressed therein should not be attributed to Ascendis Pharma.

Stay on Ascendis Pharma US Medical Website Continue to third-party website

This site is not available

outside of the US

The site is intended only for healthcare professionals in the US.

CLOSE